TAO Synergies Inc. (NASDAQ: TAOX)

Synaptogenix, Inc. (SNPX) is a biopharmaceutical company operating in the pharmaceutical industry. The company's main business activities involve researching, developing, and commercializing novel treatments for Alzheimer's disease (AD) and other neurodegenerative disorders. Synaptogenix's operations are focused on its proprietary technology platform, which is based on the drug candidate Bryostatin-1.

Bryostatin-1 is a synthetic derivative of a natural product called bryostatin, which is isolated from a marine invertebrate organism. This drug candidate has shown promise in preclinical and clinical trials as a novel therapeutic approach for AD. It targets the restoration of synaptic function and the prevention of neuronal death, thereby stimulating the regeneration of synapses, preventing the loss of neurons, and improving cognitive function in animal models of AD.

Synaptogenesis, the process of forming new synapses, is a key mechanism for neuroprotection in AD. Bryostatin-1 has been shown to stimulate synaptogenesis by activating protein kinase C epsilon (PKC ε), a key enzyme involved in synaptic plasticity. This activation leads to the formation of new synapses, which can help to restore cognitive function and prevent neuronal death.

Synaptogenix's competitive advantage lies in its proprietary technology platform and its focus on developing therapies for neurodegenerative diseases. The company's research has shown that Bryostatin-1 has a unique mechanism of action that targets the restoration of synaptic function and the prevention of neuronal death, making it a promising therapeutic approach for AD.

The market opportunity for Synaptogenix is significant, with over 50 million people worldwide estimated to have AD. The company's novel therapeutic approach has the potential to address the unmet medical need for effective treatments for AD, and its proprietary technology platform provides a competitive advantage in the market.

Synaptogenix's customers include research institutions and hospitals, as well as pharmaceutical companies that are interested in licensing its technology. The company has received funding from the National Institutes of Health and other government agencies to support its research and development efforts.

In addition to its work on Bryostatin-1, Synaptogenix has also entered into collaborative agreements with several organizations, including the Icahn School of Medicine at Mount Sinai and Cannasoul Analytics Ltd. These agreements provide the company with access to new technologies and compounds, as well as opportunities for collaboration and research.

In October 2023, Synaptogenix entered into a share purchase agreement with Cannasoul Analytics Ltd., which provided the company with a strategic investment and access to new technologies and compounds. The agreement also granted Synaptogenix certain rights in existing and future Project Subsidiaries, as well as preemptive and veto rights in connection with such Project Subsidiaries.